Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Roviello G, et al. Cancer Med. 2022 Aug;11(16):3084-3092. doi: 10.1002/cam4.4681. Epub 2022 Mar 20. Cancer Med. 2022. PMID: 35312175 Free PMC article.
Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.
Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, Roviello G, Martellucci I, Chiriacò G, Miano ST, Marzocca G, Manganelli A, Ponchietti R, Savelli V, Petrioli R. Francini F, et al. Among authors: roviello g. Prostate Cancer. 2011;2011:258689. doi: 10.1155/2011/258689. Epub 2011 Aug 21. Prostate Cancer. 2011. PMID: 22096653 Free PMC article.
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G; Multidisciplinary Oncology Group On Gastrointestinal Tumors. Petrioli R, et al. Among authors: roviello g. Cancer Invest. 2012 Jan;30(1):65-71. doi: 10.3109/07357907.2011.629380. Cancer Invest. 2012. PMID: 22236191
Targeted Therapies for Prostate Cancer.
Petrioli R, Francini E, Fiaschi AI, Laera L, Roviello G. Petrioli R, et al. Among authors: roviello g. Cancer Invest. 2015;33(7):276-85. doi: 10.3109/07357907.2015.1033105. Epub 2015 May 7. Cancer Invest. 2015. PMID: 25951372 Review.
Lenvatinib for the treatment of renal cell carcinoma.
Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N. Roviello G, et al. Expert Opin Investig Drugs. 2018 May;27(5):507-512. doi: 10.1080/13543784.2018.1472235. Epub 2018 May 14. Expert Opin Investig Drugs. 2018. PMID: 29718721 Free article. Review.
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.
Roviello G, Petrioli R, Nardone V, Rosellini P, Multari AG, Conca R, Aieta M. Roviello G, et al. Medicine (Baltimore). 2018 May;97(20):e10745. doi: 10.1097/MD.0000000000010745. Medicine (Baltimore). 2018. PMID: 29768350 Free PMC article. Clinical Trial.
422 results